Drug intelligence / Profile preview

certolizumab pegol + etanercept

Development stage: Unknown
Lead developer: UCB
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

This is a combination of two separate TNF inhibitors. Certolizumab pegol is a PEGylated Fab' fragment of a humanized TNF-alpha inhibitor monoclonal antibody that binds and neutralizes both soluble and membrane-bound TNF-alpha. Etanercept is a TNF receptor fusion protein that binds TNF. The combination is generally not recommended in clinical practice due to increased risk of infections.

Brand names: Cimzia + Enbrel

Targets

LTA (Lymphotoxin-alpha)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on certolizumab pegol + etanercept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on certolizumab pegol + etanercept.

Explore the full profile